Glioblastoma multiforme natural history: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
|||
| Line 14: | Line 14: | ||
* The median survival time from the time of diagnosis without any treatment is 3 months. Increasing age (> 60 years of age) carries a worse prognostic risk. Death is usually due to [[cerebral edema]] or increased [[intracranial pressure]]. | * The median survival time from the time of diagnosis without any treatment is 3 months. Increasing age (> 60 years of age) carries a worse prognostic risk. Death is usually due to [[cerebral edema]] or increased [[intracranial pressure]]. | ||
* With standard treatment ([[radiotherapy]], [[chemotherapy]] (such as [[temozolomide]]), and surgery), the [[median]] survival is approximately 14 months.<ref>{{cite journal | author = Stupp R, Mason W, van den Bent M, Weller M, Fisher B, Taphoorn M, Belanger K, Brandes A, Marosi C, Bogdahn U, Curschmann J, Janzer R, Ludwin S, Gorlia T, Allgeier A, Lacombe D, Cairncross J, Eisenhauer E, Mirimanoff R | title = Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. | journal = N Engl J Med | volume = 352 | issue = 10 | pages = 987-96 | year = 2005 | id = PMID 15758009}}</ref> Less than 10% of these patients survive past 5 years. | * With standard treatment ([[radiotherapy]], [[chemotherapy]] (such as [[temozolomide]]), and [[surgery]]), the [[median]] survival is approximately 14 months.<ref>{{cite journal | author = Stupp R, Mason W, van den Bent M, Weller M, Fisher B, Taphoorn M, Belanger K, Brandes A, Marosi C, Bogdahn U, Curschmann J, Janzer R, Ludwin S, Gorlia T, Allgeier A, Lacombe D, Cairncross J, Eisenhauer E, Mirimanoff R | title = Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. | journal = N Engl J Med | volume = 352 | issue = 10 | pages = 987-96 | year = 2005 | id = PMID 15758009}}</ref> Less than 10% of these patients survive past 5 years. | ||
* A study published in 2007 reported the 2-year survival at 27.3%, 3-year survival 16.7% and 4 year survival 12.9%.<ref>R. Mirimanoff , W. Mason , M. Van den Bent , R. Kortmann , M. Taphoorn , A. Brandes , S. Villa , G. Cairncrosss , T. Gorlia , R. Stupp | * A study published in 2007 reported the 2-year survival at 27.3%, 3-year survival 16.7% and 4 year survival 12.9%.<ref>R. Mirimanoff , W. Mason , M. Van den Bent , R. Kortmann , M. Taphoorn , A. Brandes , S. Villa , G. Cairncrosss , T. Gorlia , R. Stupp | ||
Revision as of 13:02, 14 September 2012
|
Glioblastoma multiforme Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Glioblastoma multiforme natural history On the Web |
|
American Roentgen Ray Society Images of Glioblastoma multiforme natural history |
|
Risk calculators and risk factors for Glioblastoma multiforme natural history |
Please help WikiDoc by adding content here. It's easy! Click here to learn about editing.
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [2]
Overview
Natural History
Prognosis
- The median survival time from the time of diagnosis without any treatment is 3 months. Increasing age (> 60 years of age) carries a worse prognostic risk. Death is usually due to cerebral edema or increased intracranial pressure.
- With standard treatment (radiotherapy, chemotherapy (such as temozolomide), and surgery), the median survival is approximately 14 months.[1] Less than 10% of these patients survive past 5 years.
- A study published in 2007 reported the 2-year survival at 27.3%, 3-year survival 16.7% and 4 year survival 12.9%.[2]
Complications
References
- ↑ Stupp R, Mason W, van den Bent M, Weller M, Fisher B, Taphoorn M, Belanger K, Brandes A, Marosi C, Bogdahn U, Curschmann J, Janzer R, Ludwin S, Gorlia T, Allgeier A, Lacombe D, Cairncross J, Eisenhauer E, Mirimanoff R (2005). "Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma". N Engl J Med. 352 (10): 987–96. PMID 15758009.
- ↑ R. Mirimanoff , W. Mason , M. Van den Bent , R. Kortmann , M. Taphoorn , A. Brandes , S. Villa , G. Cairncrosss , T. Gorlia , R. Stupp International Journal of Radiation Oncology * Biology * Physics- November 2007 1 (Vol. 69, Issue 3, Page S2, DOI: 10.1016/j.ijrobp.2007.07.004) [1]